Slide 1: Investor Presentation: FY24 Results
PharmX INVESTOR For personal use only PRESENTATION PHARMX TECHNOLOGIES LTD (ASX:PHX) FY24 Results Presentation (27 August 2024)
Slide 2: Notice & Disclaimer
NOTICE & DISCLAIMER This presentation has been prepared by PharmX Technologies Limited (PharmX or the Although the Company believes that the expectations reflected in the forward-looking For personal use only Company or PHX). It should not be considered as an offer or invitation to subscribe for, st
Slide 3: Executive Summary: Year in Review
Y E A R I N R E V I E W EXECUTIVE Summary For personal use only $6.7m $1.8m $9.9m $3.2m Growing Revenues Earnings Court Settlement Cash Position +9% on FY23 +13% on FY23 Paid in full +2% on FY23 $4m forecasted cash balance by Dec 24 $6.25m $4.49m +20% 99% Sale Proceeds Capital Return Platform Growth
Slide 4: Advancing Healthcare Through Transformative Pharma-Tech
ADVANCING HEALTHCARE THROUGH For personal use only TRANSFORMATIVE PHARMA-TECH Positioned at the heart of the pharmacy network, PharmX supports growth by connecting the industry, streamlining inventory management, and enabling smarter business decisions through data-driven solutions.
Slide 5: Leadership
P H A R M X O V E R V I E W LEADERSHIP Chairman Director Director For personal use only Nick England Jayne Shaw Dennis Bastas PharmX is an expanding business with a robust governance structure, New New guided by experts in Pharmacy, Chief Executive Director Chief Technology Officer CFO (Acting) Offi
Slide 6: Market Leader
P H A R M X O V E R V I E W MARKET LEADER For personal use only Established Extensive network Independent Empowering Australia’s pharmacy industry Connecting 99% of Australian pharmacies, Most prominent, independent, whole- for nearly two decades. 20+ POS vendors and 140 suppliers. of-market provide
Slide 7: Critical Infrastructure
P H A R M X O V E R V I E W CRITICAL INFRASTRUCTURE For personal use only 99% of Australian +20 POS & 140 Major Technology Pharmacies Intermediaries Suppliers Solutions Government Indicative illustration of companies that PharmX operates with.
Slide 8: For personal use only
P H A R M X O V E R V I E W For personal use only Used by Over Over Up to 99% 200m ~$19b 40 min of Australian order lines transacted of manual admin pharmacies transmitted annually annually saved per order
Slide 9: The PharmX Gateway EDI technology
P H A R M X O V E R V I E W The PharmX Gateway is an EDI technology that helps pharmacies and suppliers exchange information quickly and accurately. For personal use only EDI stands for “electronic data interchange” - a technology used to transfer documents and information electronically between dif
Slide 10: Marketplace
P H A R M X O V E R V I E W MARKETPLACE For personal use only +353% +428% +329% Active users Total order value Repeat orders Year-on-year growth - YE June 2024
Slide 11: Modernising Trade
P H A R M X O V E R V I E W MODERNISING Advanced checkout Fulfillment choice and multi supplier checkout. TRADE For personal use only Brand Exposure Increased brand opportunities through pharmacy-facing supplier ‘hubs’. Enriched Content Greater engagement with pharmacists through detailed product de
Slide 12: Analytics
P H A R M X O V E R V I E W ANALYTICS For personal use only Supplier Catalogue Automated Commercial insights repository replenishment & dashboards, alerts & product availability sales analytics
Slide 13: Supplier services: support and trade marketing
P H A R M X O V E R V I E W For personal use only Technical Support Trade Marketing Tailor-made solutions designed Partnership initiatives to for unique business needs fast-track growth Integrations Strategy Mapping Content Accreditation Brand Insights Promotions
Slide 14: Dominant Position: Market Research
P H A R M X O V E R V I E W DOMINANT POSITION Market Research For personal use only Strong Market Influence Defined Growth Opportunity 99% of Pharmacies see the PharmX 85% of the pharmacy market has offering to be high quality, with 76% confirmed strong appeal and viability of rating it as either 'v
Slide 15: FY24 Financial Highlights
F I N A N C I A L P E R F O R M A N C E FY24 FINANCIAL HIGHLIGHTS Continuing improvement in financial performance from growing revenue For personal use only FY24 FY24 FY23 Underlying Underlying revenue from continuing operations was Continuing up 9% on the prior period. Statutory revenue, which Oper
Slide 16: Underlying revenue growth of 9% with strong EBITDA margin
F I N A N C I A L P E R F O R M A N C E Underlying revenue growth of 9% while delivering a strong underlying EBITDA margin of 23% For personal use only FY24 FY23 Var $ Var % Statutory revenue 8,094 6,127 1,967 32% Revenue adjustments from PharmX legal case PharmX legal case revenue adjustments (1,44
Slide 17: FY24 Half-on-Half Financial Performance
F I N A N C I A L P E R F O R M A N C E FY24 HALF-ON-HALF FINANCIAL Underlying revenues continue to grow, with increasing contribution from both PharmX and PharmXchange half-on- half For personal use only Performance Underlying EBITDA in H1 benefited from the ability to allocate corproate costs to d
Slide 18: Sale of Pharmacy Software Business
F I N A N C I A L P E R F O R M A N C E SALE OF PHARMACY SOFTWARE BUSINESS Includes the loss on disposal from sale, $’000 FY24 For personal use only transaction costs and the results from Proceeds on disposal 6,250 operations until disposal Net tangible asset deficiency to be paid (245) Net proceeds
Slide 19: Operating cashflow
F I N A N C I A L P E R F O R M A N C E $’000 FY24 FY23 Var $ Var % Receipts from customers - continuing 7,066 6,585 481 7% operations Positive operating cashflow Statutory operating cashflow 3,205 10,944 7,739 (71%) Strong underlying operating cashflow delivered after adjusting for For personal use
Slide 20: Growth Accelerated by Favourable Market Conditions
L O O K I N G A H E A D GROWTH ACCELERATED BY FAVOURABLE Market Conditions For personal use only Growing population & Growth in pharmacy Increased digitisation & shifting demographics scope of practice shifting expectations Eighth Community Pharmacy Tech-enabled workforce Australia’s population is 3
Slide 21: Growth Strategy
L O O K I N G A H E A D GROWTH Analytics Supplier Strategy Capability Growth Targeted increase in direct Increased market share suppliers across the boosts purchasing activity, PharmX network and generating richer data that through vertical For personal use only further enhances our integration as t
Slide 22: Stable, Modern, Scalable
L O O K I N G A H E A D Stable Modern Scalable For personal use only PharmX plays a critical role in PharmX operates on modern The business has taken the ensuring Pharmacy orders cloud based infrastructure first steps to deliver a step The Company is now well-equipped to today, which is the first st
Slide 23: Optimise, Inform, Transform
L O O K I N G A H E A D Optimise Inform Transform For personal use only Enhancing our platforms to Our goal is to integrate analytics By working closely with our better capture and store into every customer interaction, customers, we can accurately The pharmacy industry has a wealth of data, ensurin
Slide 24: Closing Summary
Y E A R I N R E V I E W Closing Summary For personal use only $6.7m $1.8m $9.9m $3.2m Growing Revenues Earnings Court Settlement Cash Position +9% on FY23 +13% on FY23 Paid in full +2% on FY23 $4m forecasted cash balance by Dec 24 $6.25m $4.49m +20% 99% Sale Proceeds Capital Return Platform Growth Q
Slide 25: Thank You
PharmX For personal use only THANK YOU info@pharmx.com.au pharmx.com.au 1300 724 579
Slide 26: Appendices
For personal use only APPENDICES
Slide 27: Corporate Overview
CORPORATE OVERVIEW For personal use only PharmX Technologies Ltd. as at 23 August 2024 Capital Structure Share Price 4.0cps Shares on Issue (m) 598,506,789 Market Capitalisation $23.9m Options / Perf Rights (m) 19,500,000 Enterprise Value (Cash 30/06/24) $10.8m Diluted Issued Capital (m) 618,006,789
Slide 28: Profit & Loss
Profit & Loss ($’000) FY24 FY23 PCP Revenue 8,094 6,127 32% Expenses Cost of sales (1,234) (1,210) (2)% Employee benefits (2,533) (2,491) (2)% For personal use only Marketing (218) (172) (27)% Technology, communication and cloud costs (363) (421) 14% Legal fees (1,826) (1,262) (45)% PROFIT Professio
Slide 29: Cash Flow
Cash Flow ($’000) FY24 FY23 Cash flow from operating activities Receipts from customers 8,451 13,072 Payments to suppliers and employees (7,203) (11,915) Interest and other revenue received 294 109 For personal use only Proceeds from PharmX court case judgement _ 8,128 Research and development incen
Slide 30: Balance Sheet
Balance Sheet at 30 June ($’000) 2024 2023 Current assets Cash and cash equivalents 13,136 12,806 Trade and other receivables 2,271 946 Income tax receivable 883 1,659 Other assets 79 229 Assets of disposal group classified as held for sale _ 6,949 Total current assets 16,369 22,589 For personal use
Slide 31: Share Registry
Rank Name Number Held % of total shares issud 1 LUJETA PTY LTD <MARGARET A/C> 89,480,946 14.95% 2 ARROTEX INVESTMENTS HOLDING 1 PTY LTD 60,000,000 10.02% 3 BNP PARIBAS NOMINEES PTY LTD 39,170,392 6.54% 4 MERSAULT PTY LTD 26,766,667 4.47% For personal use only 5 HSBC CUSTODY NOMINEES (AUSTRALIA) LIMI